Europe's stuttering vaccine rollout faced multiple hurdles as EU regulators said they were reviewing side effects of the Johnson & Johnson (Janssen) shot and France further limited its use of the AstraZeneca jab.
There are currently no guidelines on the "mixing and matching" of COVID-19 vaccines, the European Medicines Agency (EMA) clarified on Wednesday (7 April), as several European countries are now considering mixed vaccination strategies.
Britain on Sunday (21 March) warned the European Union against halting exports of AstraZeneca's Covid-19 vaccines if the bloc does not receive promised deliveries, saying such a move would be "counter-productive".
The EU's largest countries joined a stream of states halting their rollouts of AstraZeneca jabs on Monday (15 March) over blood clot fears, as the World Health Organization and Europe's medicines watchdog insisted it was safe to use.
Spanish biopharmaceutical group Zendal wrote to Spain's industry minister declaring its interest in producing Russia's Sputnik V coronavirus vaccine in the country, an industry ministry spokeswoman said on Wednesday (10 March).
Russia's Sputnik V vaccine against COVID-19 could be produced in Europe for the first time after a commercial deal to produce it in Italy was signed by the Moscow-based RDIF sovereign wealth fund and Swiss-based pharmaceutical company Adienne.
A senior European Medicines Agency (EMA) official urged European Union members on Sunday (7 March) to refrain from granting national approvals for Russian COVID-19 vaccine Sputnik V while the agency reviews its safety and effectiveness.
Slovakia has dumped a plan to negotiate with Russia to buy the Sputnik V vaccine, after a junior coalition partner vetoed buying a product which has not been registered by the European Medicines Agency, Prime Minister Igor Matovič said.
The European drugs regulator could soon give the go ahead for an extra sixth dose to be extracted from Pfizer-BioNTech COVID-19 vaccine vials, lifting the number of available shots at a time when supplies are short.
The European Union could authorise a second coronavirus vaccine "in the coming hours", European Council chief Charles Michel said Tuesday (5 January), adding that leaders would hold a virtual summit on the health crisis later this month.
Europe's drug regulator is under increasing pressure to quickly approve the COVID-19 vaccine developed by US giant Pfizer and Germany's BioNTech, officials said, as inoculations get started in Britain and the United States.
Two pharmaceutical companies in line for first conditional approval for their Covid-19 vaccine by the EU's medicine regulator said Wednesday (9 December) their documents were "unlawfully accessed" during a cyberattack on a European Medicines Agency server.
The European Union criticised Britain’s rapid approval of Pfizer and BioNTech’s COVID-19 vaccine on Wednesday (2 December), saying its own procedure was more thorough, while US health experts welcomed the British move as a sign US regulators should follow suit.
Scepticism about adverse effects and actual lack of efficacy in immunisation practices can become an important negative factor when a vaccine against coronavirus becomes available, according to the head of the EU's medicines agency (EMA), Guido Rasi.
A strong EU regulatory framework on medical cannabis is needed to provide investors with stability but also to give peace of mind to patients struggling with fragmented legislation among member states, socialist MEP Miriam Dalli said.